Syndax Pharmaceuticals, Inc. Retained Earnings
Syndax Pharmaceuticals, Inc. (SNDX) had Retained Earnings of -$1.60 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-04
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$1.60B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$1.55B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$1.51B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$1.44B.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$1.60B 10-Q · filed 2026-08-04 |
| 2026-03-31 | -$1.55B 10-Q · filed 2026-04-30 |
| 2025-12-31 | -$1.51B 10-Q · filed 2026-08-04 |
| 2025-09-30 | -$1.44B 10-Q · filed 2025-11-03 |
| 2025-06-30 | -$1.38B 10-Q · filed 2025-08-04 |
| 2025-03-31 | -$1.31B 10-Q · filed 2025-05-05 |
| 2024-12-31 | -$1.22B 10-K · filed 2026-02-26 |
| 2024-09-30 | -$1.13B 10-Q · filed 2024-11-05 |
| 2024-06-30 | -$1.04B 10-Q · filed 2024-08-01 |
| 2024-03-31 | -$974.80M 10-Q · filed 2024-05-08 |
| 2023-12-31 | -$902.40M 10-K · filed 2025-03-03 |
| 2023-09-30 | -$829.93M 10-Q · filed 2023-11-02 |
| 2023-06-30 | -$778.78M 10-Q · filed 2023-08-03 |
| 2023-03-31 | -$734.17M 10-Q · filed 2023-05-08 |
| 2022-12-31 | -$693.04M 10-K · filed 2024-02-27 |
| 2022-09-30 | -$653.85M 10-Q · filed 2022-11-03 |
| 2022-06-30 | -$618.44M 10-Q · filed 2022-08-08 |
| 2022-03-31 | -$580.87M 10-Q · filed 2022-05-09 |
| 2021-12-31 | -$543.70M 10-K · filed 2023-02-28 |
| 2021-09-30 | -$639.90M 10-Q · filed 2021-11-15 |
| 2021-06-30 | -$619.26M 10-Q · filed 2021-08-09 |
| 2021-03-31 | -$596.35M 10-Q · filed 2021-05-11 |
| 2020-12-31 | -$568.63M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$548.21M 10-Q · filed 2020-11-05 |
| 2020-06-30 | -$527.77M 10-Q · filed 2020-08-06 |
| 2020-03-31 | -$510.71M 10-Q · filed 2020-05-07 |
| 2019-12-31 | -$495.47M 10-K · filed 2021-03-12 |
| 2019-09-30 | -$481.47M 10-Q · filed 2019-11-07 |
| 2019-06-30 | -$468.64M 10-Q · filed 2019-08-07 |
| 2019-03-31 | -$453.73M 10-Q · filed 2019-05-08 |
| 2018-12-31 | -$439.42M 10-K · filed 2020-03-05 |
| 2018-09-30 | -$420.59M 10-Q · filed 2018-11-05 |
| 2018-06-30 | -$403.25M 10-Q · filed 2018-08-08 |
| 2018-03-31 | -$384.86M 10-Q · filed 2018-05-09 |
| 2017-12-31 | -$366.11M 10-K · filed 2019-03-07 |
| 2017-09-30 | -$347.01M 10-Q · filed 2017-11-08 |
| 2017-06-30 | -$331.92M 10-Q · filed 2017-08-10 |
| 2017-03-31 | -$318.28M 10-Q · filed 2017-05-09 |
| 2016-12-31 | -$305.29M 10-K · filed 2018-03-08 |
| 2016-09-30 | -$294.48M 10-Q · filed 2016-11-14 |
| 2016-06-30 | -$279.51M 10-Q · filed 2016-08-15 |
| 2016-03-31 | -$271.15M 10-Q · filed 2016-05-16 |
| 2015-12-31 | -$259.68M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |